Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07452224) titled 'ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer' on Feb. 28.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: iLeukon Therapeutics, Inc.
Condition:
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Intervention:
Drug: ILKN421H
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 2026
Target Sample Size: 80
To know more, visit https://clinicaltrials.gov/study/NCT07452224
Published by HT Digital Content Ser...